Buhl R, et al. - DACCORD is a non-interventional, observational clinical study that enrolled subjects following COPD maintenance therapy initiation or change in maintenance therapy between or within therapeutic class to assess the “real-world” effectiveness of dual bronchodilation comprising a long-acting β₂-agonist plus a long-acting muscarinic antagonist vs that of triple therapy (long-acting β₂-agonist plus long-acting muscarinic antagonist plus inhaled corticosteroid) in COPD. Most of whom had not exacerbated in the 6 months prior to entry, triple therapy did not appear to improve outcomes compared with dual bronchodilation in terms of either exacerbations or health status in this “real-life” cohort of patients with COPD. The greatest COPD Assessment Test total score improvement was noted among those changing from mono-bronchodilator to dual bronchodilation.